Pharmaron Beijing Co., Ltd. Class H (HK:3759)
:3759
Want to see HK:3759 full AI Analyst Report?
3759 Stock Chart & Stats
HK$24.14
HK$0.24(1.88%)
At close: 4:00 PM EST
HK$24.14
HK$0.24(1.88%)
Day’s Range― - ―
52-Week RangeHK$13.32 - HK$30.12
Previous CloseN/A
Volume1.90M
Average Volume (3M)3.76M
Market Cap
HK$51.05B
Enterprise ValueHK$44.12B
Total Cash (Recent Filing)HK$2.97B
Total Debt (Recent Filing)HK$7.08B
Price to Earnings (P/E)22.4
Beta1.98
Next Earnings
Aug 31, 2026EPS Estimate
0.29Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)0.95
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio-2.69
Price to Book (P/B)2.06
Price to Sales (P/S)2.20
P/FCF Ratio56.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$28.75Price Target Upside19.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$18.63B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetLow TTM debt-to-equity (~0.23) and growing shareholders' equity provide a durable financial buffer. This supports capital-intensive CDMO operations, funds strategic investments or capacity expansion without immediate refinancing risk, and improves resilience through industry cycles.
Integrated Drug R&D + Manufacturing ModelA full-lifecycle service model (discovery through manufacturing) creates diversified fee-for-service streams and cross-selling opportunities. Structural outsourcing trends in pharma favor integrated CDMO/CRDMO vendors, increasing client stickiness and lifetime value over multiple project phases.
Healthy Profitability And MarginsSustained mid-teens EBIT and double-digit net margins indicate underlying operational efficiency and pricing power in specialized R&D/manufacturing services. Healthy margins support reinvestment in capacity, R&D capabilities and maintain returns on equity over the medium term.
Bears Say
Weak, Volatile Free Cash FlowLow and volatile FCF relative to earnings (OCF-to-net-income ~0.39) limits financial flexibility for capex, debt reduction, or buybacks. Persistent volatility and past negative FCF years raise funding risk if growth or working-capital demands rise, pressuring long-term cash returns.
Slowing Revenue Growth TrajectoryTTM growth slowed to ~3.2% from stronger prior periods, reducing the pace at which scale benefits and cross-sell synergies can compound. Slower top-line expansion may constrain margin recovery and make it harder to invest in capacity without sacrificing near-term returns.
Margin Compression Since 2021Material margin deterioration since 2021 points to structural cost pressures, competitive pricing or adverse mix. Sustained compression weakens cash generation and return metrics, reducing ability to fund growth internally and potentially eroding long-term competitive advantage.
Pharmaron Beijing Co., Ltd. Class H News
3759 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$13.32 and its highest was HK$30.12 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$51.05B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 102 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Apr 28, 2026. The company reported HK$0.212 earnings per share for the quarter, missing the consensus estimate of HK$0.24 by -HK$0.028.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Undervalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays a Annually dividend of HK$0.219 which represents an annual dividend yield of 1.04%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.29.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.212 in its last earnings report, missing expectations of HK$0.24. Following the earnings report the stock price went up 5.922%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
11.22%
Trailing 12-Months
Asset Growth
15.52%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. Class H (3759) is a leading contract research organization (CRO) offering a comprehensive range of R&D and manufacturing services to the pharmaceutical and biotechnology sectors. Founded in Beijing, China, Pharmaron provides integrated services in discovery, development, and manufacturing, covering various stages of drug research and production. The company's core services include drug discovery, preclinical research, clinical development, and commercial manufacturing, serving clients across the globe.
3759 Stock 12 Month Forecast
Average Price Target
HK$28.75
▲(19.09% Upside)
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---